| Literature DB >> 28573470 |
M B F Jensen1, S Schjørring1,2, J T Björkman1, M Torpdahl1, E Litrup1, E M Nielsen3, T Niskanen4.
Abstract
We report the results of three consecutive External Quality Assessments (EQAs) for molecular subtyping of Salmonella to assess the performance of the European national public health reference laboratories (NPHRLs). The EQA included the molecular typing methods used for European enhanced surveillance of human Salmonella infections: pulsed field gel electrophoresis (PFGE), including gel analysis by the use of the software BioNumerics, and 5-locus multiple locus variable number of tandem repeat analysis (MLVA) for serovar Typhimurium. The participation in the PFGE laboratory part was higher (27/35) than in the gel analysis (19/35) and MLVA (15/35), suggestive of the need for capacity building in methods requiring specialized equipment (MLVA) or software (gel analysis). The majority (25/27) of the participating NPHRLs produced inter-laboratory comparable PFGE gel(s). Two laboratories continued to produce low-quality gels and should have additional technical assistance in the future. In particular, two gel quality evaluation parameters, measuring "image acquisition and running conditions" and "bands", were identified to cause gel quality problems throughout the EQAs. Despite the high number of laboratories participating in the PFGE laboratory part, the participation in gel analysis was low, although increasing. In the MLVA part, the NPHRLs correctly assigned 96% (405/420) allelic profiles according to the nomenclature. In conclusion, the EQAs identified critical parameters for unsuccessful performance and helped to offer assistance to those laboratories that needed it most. The assessments supported the development of quality in molecular typing and promoted the harmonization of subtyping methods used for EU/EEA-wide surveillance of human Salmonella infections.Entities:
Mesh:
Year: 2017 PMID: 28573470 PMCID: PMC5602099 DOI: 10.1007/s10096-017-3015-7
Source DB: PubMed Journal: Eur J Clin Microbiol Infect Dis ISSN: 0934-9723 Impact factor: 3.267
Salmonella serovars included for PFGE typing in each Salmonella EQA round, 2013–2015
| EQA | Test strain |
|
|---|---|---|
| 2013 | 1–10 | Enteritidis (two strains), Infantisa, Kentucky, Mbandaka, Montevideo, O:4,5,12;H:i:-, Poona, Stanleyb, and Strathcona |
| 2014 | 1–10 | Agona, Enteritidis, Hadar, Infantisa, Manhattan, Mikawasima, O:4,5,12;H:i:-, Poona, Stanleyb, and Typhimurium |
| 2015 | 1–10 | Chester, Enteritidis, Infantisa, Java, Javiana, O:4,5,12;H:i:-, Poona, Reading, Stanleyb, and Typhimurium |
Repeat strains (a and b) included in all EQA rounds
Allelic profiles included for MLVA of Salmonella Typhimurium in each Salmonella EQA round, 2013–2015
| EQA | Test strain | MLVA | ||||
|---|---|---|---|---|---|---|
| Allelic profile | ||||||
| STTR9 | STTR5 | STTR6 | STTR10 | STTR3 | ||
| 2013 | 11 | 2 | 15 | 7 | 10 | 212 |
| 12 | 4 | 20 | 7 | 7 | 212 | |
| 13 | 2 | 20 | 13 | 12 | 12 | |
| 14a | 3 | 13 | NA | NA | 211 | |
| 15 | 3 | 14 | 9 | NA | 211 | |
| 16b | 3 | 12 | 9 | NA | 211 | |
| 17 | 3 | 18 | 11 | NA | 211 | |
| 18 | 3 | 15 | NA | NA | 111 | |
| 19 | 3 | 14 | 11 | 3 | 309 | |
| 20c | 3 | 16 | 15 | 23* | 311 | |
| 2014 | 11 | 2 | 11 | 8 | 9 | 212 |
| 12 | 2 | 13 | 3 | NA | 212 | |
| 13 | 2 | 20 | 9 | 7 | 212 | |
| 14 | 3 | 10 | 10 | NA | 211 | |
| 15b | 3 | 12 | 9 | NA | 211 | |
| 16a | 3 | 13 | NA | NA | 211 | |
| 17 | 3 | 13 | 9 | NA | 211 | |
| 18c | 3 | 16 | 15 | 23* | 311 | |
| 19 | 3 | 18 | 11 | NA | 211 | |
| 20 | 4 | 16 | 9 | 9 | 211 | |
| 2015 | 11b | 3 | 12 | 9 | NA | 211 |
| 12 | 5 | 19 | 9 | 11 | 211 | |
| 13 | 2 | 15 | 7 | 9 | 212 | |
| 14 | 4 | 17 | 13 | 9 | 111 | |
| 15a | 3 | 13 | NA | NA | 211 | |
| 16 | 3 | 11 | 11 | NA | 211 | |
| 17 | 8 | 14 | NA | NA | 211 | |
| 18c | 3 | 16 | 15 | 24* | 311 | |
| 19 | 3 | 12 | 6 | NA | 211 | |
| 20 | 3 | 18 | 14 | 15 | 311 | |
Repeat strain (a–c) included in all EQA rounds. Repeat strain c had gained a repeat in the STTR10 locus before distribution in the 2015-EQA
NA not applicable (locus not present) [12]
*Single locus variants (SLV) of the repeat strain c in STTR10
Number of laboratories submitting results to the Salmonella EQA rounds by method and year, 2013–2015
| EQA | PFGE, | MLVA, | ||
|---|---|---|---|---|
| Gel | Gel and analysis | Total (%) | ||
| 2013 ( | 6 | 16 | 22 (92) | 14 (58) |
| 2014 ( | 8 | 17 | 25 (96) | 14 (54) |
| 2015 ( | 8* | 17 | 25 (93) | 14 (54) |
Gel Submission of PFGE gel image
Gel and analysis Submission of PFGE gel image including profile analysis in BioNumerics
*One laboratory submitted an un-analysable PFGE gel due to major technical problems, and was excluded from analyses, thus n = 7 evaluated results
Individual laboratory PFGE gel quality result (acceptable or non-acceptable) in Salmonella EQA rounds by year, 2013–2015
| Number of EQAs (no. of participants) | Laboratory number | Performance level | Total percentage scorea | ||||
|---|---|---|---|---|---|---|---|
| 2013 | 2014 | 2015 | 2013 | 2014 | 2015 | ||
| 3 ( | 92 | 1 | 1 | 1 | 100 | 100 | 93 |
| 147 | 1 | 1 | 1 | 100 | 96 | 100 | |
| 19 | 1 | 1 | 1 | 96 | 100 | 82 | |
| 36 | 1 | 1 | 1 | 93 | 96 | 96 | |
| 55 | 1 | 1 | 1 | 93 | 86 | 86 | |
| 106 | 1 | 1 | 1 | 89 | 96 | 75 | |
| 49 | 1 | 1 | 1 | 86 | 89 | 86 | |
| 134 | 1 | 1 | 1 | 82 | 96 | 82 | |
| 100 | 1 | 1 | 1 | 82 | 89 | 86 | |
| 77 | 1 | 1 | 1 | 71 | 89 | 75 | |
| 128 | 1 | 0 | 1 | 79 | 82 | 89 | |
| 142 | 1 | 0 | 1 | 71 | 64 | 89 | |
| 130 | 1 | 1 | 0 | 79 | 82 | 64 | |
| 144 | 1 | 1 | 0 | 79 | 79 | 68 | |
| 129 | 1 | 1 | 0 | 75 | 93 | 86 | |
| 138 | 1 | 0 | 0 | 86 | 64 | 71 | |
| 114 | 0 | 1 | 1 | 82 | 79 | 79 | |
| 140 | 0 | 1 | 1 | 82 | 93 | 93 | |
| 148 | 0 | 0 | 1 | 64 | 54 | 75 | |
| 132 | 0 | 0 | 0 | 75 | 64 | 68 | |
| 2 ( | 150 | 1 | 1 | – | 82 | 75 | – |
| 108 | – | 1 | 1 | – | 79 | 86 | |
| 145 | – | 0 | 1 | – | 71 | 71 | |
| 160 | – | 0 | 0 | – | 79 | 64 | |
| 1 ( | 406 | 1 | – | – | 79 | – | – |
| 125 | – | 1 | – | – | 75 | – | |
| 180 | – | – | 1 | – | – | 89 | |
1 acceptable gel, 0 non-acceptable gel, – no participation
aTotal percentage score of the maximum score of 28 points
Number of non-acceptable PFGE gel scores and average score in Salmonella EQA rounds by parameter and year, 2013–2015
| Parameter | Condition of excellent score [ | No. of non-acceptable gels (%) | Average score | ||||
|---|---|---|---|---|---|---|---|
| 2013 | 2014 | 2015 | 2013 | 2014 | 2015 | ||
| Image acquisition and | Wells included, bottom band 1.5 cm from edge, and spacing of standard match global standard | 2 (9%) | 2 (8%) | 3 (13%) | 2.4 | 3.0 | 2.9 |
| Cell suspension | Even distribution of DNA | 0 | 0 | 0 | 3.9 | 4.0 | 3.6 |
| Bands | Clear and distinct bands | 2 (9%) | 7 (28%) | 5 (21%) | 2.5 | 2.5 | 2.5 |
| Lanes | Straight lanes | 0 | 0 | 0 | 3.8 | 3.7 | 3.6 |
| Restriction | Complete restriction in all lanes | 0 | 2 (8%) | 0 | 3.8 | 3.7 | 3.8 |
| Gel background | Clear background | 0 | 0 | 0 | 3.3 | 2.9 | 3.3 |
| DNA degradation | No degradation | 0 | 2 (8%) | 0 | 3.5 | 3.5 | 3.1 |
Scores given according to the TIFF Quality Grading Guidelines [18–20]. Score of 1: non-acceptable, scores of 2, 3 or 4: acceptable
Individual laboratory gel analysis quality result (acceptable or non-acceptable) in Salmonella EQA rounds by year, 2013–2015
| Number of EQAs (no. of participants) | Laboratory number | Performance level | Total percentage scorea | ||||
|---|---|---|---|---|---|---|---|
| 2013 | 2014 | 2015 | 2013 | 2014 | 2015 | ||
| 3 ( | 19 | 1 | 1 | 1 | 100 | 100 | 80 |
| 147 | 1 | 1 | 1 | 100 | 93 | 93 | |
| 36 | 1 | 1 | 1 | 100 | 93 | 93 | |
| 49 | 1 | 1 | 1 | 100 | 93 | 93 | |
| 77 | 1 | 1 | 1 | 100 | 93 | 93 | |
| 92 | 1 | 1 | 1 | 100 | 87 | 87 | |
| 142 | 1 | 1 | 1 | 93 | 93 | 93 | |
| 134 | 1 | 1 | 1 | 93 | 93 | 93 | |
| 106 | 1 | 1 | 1 | 93 | 87 | 100 | |
| 55 | 1 | 1 | 1 | 87 | 93 | 93 | |
| 148 | 1 | 0 | 1 | 87 | 53 | 73 | |
| 130 | 1 | 0 | 1 | 80 | 67 | 73 | |
| 129 | 0 | 1 | 1 | 87 | 93 | 93 | |
| 128 | 0 | 0 | 1 | 73 | 67 | 100 | |
| 2 ( | 150 | 1 | 1 |
| 93 | 87 |
|
| 100 |
| 1 | 1 |
| 100 | 100 | |
| 108 |
| 1 | 1 |
| 100 | 87 | |
| 1 ( | 406 | 1 |
|
| 87 |
|
|
| 132 |
|
| 1 |
|
| 93 | |
Scores given according to the BioNumerics Gel Quality Grading Guidelines, [18–20]. 1 acceptable gel, 0 non-acceptable gel, – no participation
aTotal percentage score of the maximum score of 15 points
Number of non-acceptable PFGE gel analyses, average score in Salmonella EQA by parameters and by year, 2013–2015
| Parameter | Condition for excellent score (3) | No. of non-acceptable analyses (%) | Average score | ||||
|---|---|---|---|---|---|---|---|
| 2013 | 2014 | 2015 | 2013 | 2014 | 2015 | ||
| Position of frame | Correct placement of frame and gel inverted | 1 (6%) | 1 (6%) | 0 | 2.6 | 2.4 | 2.6 |
| Strips | All lanes correctly defined | 0 | 0 | 0 | 2.9 | 2.3 | 2.6 |
| Curves | 1/3 of the lanes used for averaging curve thickness | 0 | 0 | 0 | 2.7 | 2.7 | 2.9 |
| Normalization | All bands correctly assigned in all reference lanes | 0 | 2 (11%) | 0 | 2.8 | 2.5 | 2.8 |
| Band assignment | Bands assigned correctly according to gel quality | 1 (6%) | 1 (6%) | 0 | 2.8 | 2.6 | 2.6 |
Scores given according to the BioNumerics Gel Quality Grading Guidelines, [18–20]. Scores of 1: non-acceptable gel, scores of 2 or 3: acceptable
Individual laboratory MLVA result in Salmonella EQA rounds by year, 2013–2015
| Number of EQAs (no. of participants) | Laboratory number | Number of correct MLVA profiles | |||||
|---|---|---|---|---|---|---|---|
| Test strains ( | Repeat strains ( | ||||||
| 2013 | 2014 | 2015 | 2013 | 2014 | 2015 | ||
| 3 ( | 19 | 10 | 10 | 10 | 3 | 3 | 3 |
| 36 | 10 | 10 | 10 | 3 | 3 | 3 | |
| 129 | 10 | 10 | 10 | 3 | 3 | 3 | |
| 134 | 10 | 10 | 10 | 3 | 3 | 3 | |
| 147 | 10 | 10 | 10 | 3 | 3 | 3 | |
| 149 | 10 | 10 | 10 | 3 | 3 | 3 | |
| 100 | 10 | 7 | 10 | 3 | 2 | 3 | |
| 77 | 10 | 9 | 8 | 3 | 2 | 2 | |
| 49 | 9 | 10 | 10 | 3 | 3 | 3 | |
| 142 | 9 | 10 | 10 | 3 | 3 | 3 | |
| 144 | 8 | 10 | 10 | 3 | 3 | 3 | |
| 148 | 10 | 9 | 10 | 3 | 3 | 3 | |
| 2 ( | 150 | 10 | 10 | – | 3 | 3 | – |
| 88 | 10 | – | 6 | 3 | – | 2 | |
| 108 | – | 10 | 10 | – | 3 | 3 | |